Using living cells to treat – and sometimes even cure – cancer is one of the most dramatic advances in modern medicine. Patients with hematologic malignancies have been successfully treated with cell therapies. However, these profound results have not yet been achieved in patients with solid tumors, representing approximately 90% of all cancers. And for patients with hematologic malignancies, there is a need for next-generation cell therapies that can deliver increased response rates and longer duration of response. We are a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with solid tumors or hematologic malignancies. Lyell’s product candidates are enhanced with novel technology designed to generate T cells that resist exhaustion and have qualities of durable stemness in order to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical response. We were founded by cell therapy pioneers whose decades of research elevated the broader understanding of T-cell biology and its interaction with cancer. In our quest to advance next-generation CAR T-cell therapies, we have built a fully integrated company capable of discovering new technologies, translating science into therapies, manufacturing cell therapy products, and clinically evaluating them in patients. Our culture is based on Science, Respect, Collaboration, and Courage and reflects who we are, the environment we create, and our mission's urgency. At Lyell, our vision is to develop curative cell-based immunotherapies for solid tumor cancers. We have innovative science originating from our founder’s world class labs and a unique and disruptive approach to research and development. Our company is first and foremost focused on understanding the science. We are a learning organization, dependent on deep collaborative relationships between all of our colleagues, partners and founders. Our culture is based on Respect, Science, Courage and Collaboration and it reflects who we are and the environment we are creating. The Chief Financial Officer is an integral member of, and serves as a key strategic partner to, the Lyell Leadership Team (“LLT”), providing leadership, advice and perspective on significant business and financial decisions. S/he will be responsible for the development and execution of the finance strategy to support the Company’s goals and vision, and for completing business development transactions to advance the business. The CFO will also play a lead role in positioning Lyell externally while providing input, advice and perspective on all significant business decisions. The CFO will be a strong voice in the setting of strategic and operating plans, particularly as it relates to the financial profile of the Company. The CFO will lead the financial operations and ensure that the leadership and the Board of Directors (“Board”) have a clear understanding of operating performance and risks as it relates to all budgeted and forecasted goals. The ideal candidate will be a seasoned leader who demonstrates sound business judgment, financial leadership, while instilling best practices supported by analysis, data and metrics. He/she will bring a high level of intellectual curiosity and emotional intelligence with a track record as a strong leader. The proven ability to work with and communicate with his/her peers across all functions (Research, Clinical Development, Information Sciences/IT, Technical Operations/Supply Chain, Business Development, Legal, People Team, etc.) is essential.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Executive